Compounds > naproxen
Page last updated: 2024-09-04

naproxen and zithromax

naproxen has been researched along with zithromax in 10 studies

Compound Research Comparison

Studies
(naproxen)		Trials
(naproxen)		Recent Studies (post-2010)
(naproxen)		Studies
(zithromax)		Trials
(zithromax)		Recent Studies (post-2010) (zithromax)
4,5511,0571,4296,9641,2633,790

Protein Interaction Comparison

ProteinTaxonomynaproxen (IC50)zithromax (IC50)
30S ribosomal protein S6Escherichia coli K-120.3
30S ribosomal protein S7Escherichia coli K-120.3
50S ribosomal protein L15Escherichia coli K-120.3
50S ribosomal protein L10Escherichia coli K-120.3
50S ribosomal protein L11Escherichia coli K-120.3
50S ribosomal protein L7/L12Escherichia coli K-120.3
50S ribosomal protein L19Escherichia coli K-120.3
50S ribosomal protein L1Escherichia coli K-120.3
50S ribosomal protein L20Escherichia coli K-120.3
50S ribosomal protein L27Escherichia coli K-120.3
50S ribosomal protein L28Escherichia coli K-120.3
50S ribosomal protein L29Escherichia coli K-120.3
50S ribosomal protein L31Escherichia coli K-120.3
50S ribosomal protein L31 type BEscherichia coli K-120.3
50S ribosomal protein L32Escherichia coli K-120.3
50S ribosomal protein L33Escherichia coli K-120.3
50S ribosomal protein L34Escherichia coli K-120.3
50S ribosomal protein L35Escherichia coli K-120.3
50S ribosomal protein L36Escherichia coli K-120.3
30S ribosomal protein S10Escherichia coli K-120.3
30S ribosomal protein S11Escherichia coli K-120.3
30S ribosomal protein S12Escherichia coli K-120.3
30S ribosomal protein S13Escherichia coli K-120.3
30S ribosomal protein S16Escherichia coli K-120.3
30S ribosomal protein S18Escherichia coli K-120.3
30S ribosomal protein S19Escherichia coli K-120.3
30S ribosomal protein S20Escherichia coli K-120.3
30S ribosomal protein S2Escherichia coli K-120.3
30S ribosomal protein S3Escherichia coli K-120.3
30S ribosomal protein S4Escherichia coli K-120.3
30S ribosomal protein S5Escherichia coli K-120.3
30S ribosomal protein S8Escherichia coli K-120.3
30S ribosomal protein S9Escherichia coli K-120.3
50S ribosomal protein L13Escherichia coli K-120.3
50S ribosomal protein L14Escherichia coli K-120.3
50S ribosomal protein L16Escherichia coli K-120.3
50S ribosomal protein L23Escherichia coli K-120.3
30S ribosomal protein S15Escherichia coli K-120.3
50S ribosomal protein L17Escherichia coli K-120.3
50S ribosomal protein L21Escherichia coli K-120.3
50S ribosomal protein L30Escherichia coli K-120.3
50S ribosomal protein L6Escherichia coli K-120.3
30S ribosomal protein S14Escherichia coli K-120.3
30S ribosomal protein S17Escherichia coli K-120.3
30S ribosomal protein S1Escherichia coli K-120.3
50S ribosomal protein L18Escherichia coli K-120.3
50S ribosomal protein L2Escherichia coli K-120.3
50S ribosomal protein L3Escherichia coli K-120.3
50S ribosomal protein L24Escherichia coli K-120.3
50S ribosomal protein L4Escherichia coli K-120.3
50S ribosomal protein L22Escherichia coli K-120.3
50S ribosomal protein L5Escherichia coli K-120.3
30S ribosomal protein S21Escherichia coli K-120.3
50S ribosomal protein L25Escherichia coli K-120.3
50S ribosomal protein L36 2Escherichia coli K-120.3

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's7 (70.00)24.3611
2020's2 (20.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Azadi, H; Darabi, E; Fathi, S; Ghanei, M; Ghazale, AH; Ghazvini, A; Izadi, M; Jafari, R; Movaseghi, F; Mozafari, A; Panahi, Y; Parsaei, MR; Ranjkesh, MH; Rezapour, M; Saadat, SH; Salesi, M; Vahedi, E; Zand, N1

Reviews

1 review(s) available for naproxen and zithromax

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

9 other study(ies) available for naproxen and zithromax

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:1

    Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2020, Volume: 28, Issue:2

    Topics: Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Iran; Length of Stay; Levofloxacin; Lopinavir; Male; Meropenem; Middle Aged; Naproxen; Oseltamivir; Pneumonia, Viral; Prednisolone; Retrospective Studies; Ritonavir; Treatment Outcome; Vancomycin

2020